Idorsia Company Profile

Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is specialized in the discovery, development, and commercialization of transformative medicines.

We have a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients.

Financial overview — **First Quarter**

in CHF millions, except EPS (CHF) and number of shares (millions)	US GAAP 2025	US GAAP 2024	Non-GAAP* 2025	Non-GAAP* 2024
Net revenues	59	10	58	10
Operating expenses	5	20	(78)	(96)
Operating income (loss)	67	31	(17)	(85)
Net income (loss)	63	30	(25)	(86)
Basic EPS	0.33	0.17	(0.13)	(0.48)
Basic weighted average number of shares	188.9	179.1	188.9	179.1
Diluted EPS	0.23	0.13	(0.13)	(0.48)
Diluted weighted average number of shares	270.8	233.3	188.9	179.1

The full financial statements can be found in the Financial Report available on our corporate website.

* Idorsia measures, reports and issues guidance on non-GAAP operating performance. Idorsia believes that these non-GAAP financial measurements more accurately reflect the underlying business performance and therefore provide useful supplementary information to investors. These non-GAAP measures are reported in addition to, not as a substitute for, US GAAP financial performance.

Share Information

Idorsia was incorporated in March 2017 and listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017.

Idorsia Ltd is part of the following indices: SPI, SPIEX, SPI ESG, SXSLI, SXI Life Sciences, SXI Bio+Medtech, and SSIRT.

Idorsia is traded under the following symbols:
Reuters IDIA.S / Bloomberg IDIA:SW.

Company Strategy

We will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. We have identified five key strategic priorities to ensure the company's success going forward.

Unlocking the value of QUVIVIQ
We must overcome the barriers to prescription wherever we find them, to awaken the value of QUVIVIQ for all our stakeholders.

Nurturing our strong alliances
Idorsia often retains a vested interest in the success of our partnered products. Supporting our partners will maximize the value of our innovation.

Leveraging our innovative pipeline
To attract potential partners, the R&D team will generate preclinical and clinical evidence enabling others to recognize the value of our innovation in a portfolio for out-licensing.

Targeting our drug discovery
Our specialized drug discovery engine will focus on small-molecule therapies designed to redefine the way diseases are treated.

Making the money last
We will exercise financial discipline, spending within our means, and thus paving the way to sustainable profitability.

Innovation portfolio

Idorsia-led

The company will develop each asset to the next inflection point or seek a partner

Compound	Target indication	Mechanism of action	P1	P2	P3	R	C	Status
QUVIVIQ™ (daridorexant)	Insomnia	Dual orexin receptor antagonist	■	■	■	■	■	Commercially available in the US, Germany, Italy, Switzerland, Spain, the UK, Canada, Austria, France, and Sweden; approved throughout the EU
Lucerastat	Fabry disease	Glucosylceramide synthase inhibitor	■	■	■	□	□	Phase 3 open-label extension study ongoing – kidney biopsy sub-study results expected in Q2 2025 – regulatory pathway to be further discussed with FDA
Daridorexant	Pediatric insomnia	Dual orexin receptor antagonist	■	■	□	□	□	Phase 2 in pediatric insomnia ongoing
ACT-777991	Vitiligo	CXCR3 antagonist	■	■	□	□	□	Proof-of-concept study in preparation
ACT-1004-1239	Progressive multiple sclerosis	ACKR3 (CXCR7) receptor antagonist	■	■	□	□	□	Proof-of-concept study in preparation
IDOR-1117-2520	Psoriasis	CCR6 receptor antagonist	■	□	□	□	□	Proof-of-concept study in preparation
ACT-1016-0707	Immune-mediated and fibrosis related disorders	LPA 1 receptor antagonist	□	□	□	□	□	Entry-into-human package complete
IDOR-1134-9712	Cystic Fibrosis	CFTR Type-IV corrector	□	□	□	□	□	Entry-into-human package in progress
IDOR-1126-6421	Organ injury / fibrosis	Undisclosed mechanism	□	□	□	□	□	Entry-into-human package in progress
IDOR-1141-8472	Orexin-related CNS disorders	Orexin 2 receptor agonist	□	□	□	□	□	Entry-into-human package ready to begin
Synthetic Glycan Vaccine Platform			Idorsia will seek a partner for the platform or individual vaccines					
IDOR-1134-2831	*Clostridium difficile* infection	Synthetic glycan vaccine	■	□	□	□	□	Idorsia is conducting a Phase 1 clinical pharmacology study – Results expected in Q2 2025.
IDOR-1142-0810	*Klebsiella pneumonia* infection	Synthetic glycan vaccine	□	□	□	□	□	Entry-into-human package in progress

P1: Phase 1, P2: Phase 2, P3: Phase 3, R: Registration, C: Commercially available
For more information about our portfolio please read our **Innovation fact sheet**.

Innovation portfolio

Partner-led

Compound	Target indication	Mechanism of action	Partner Terms	P1	P2	P3	R	C	Status
TRYVIO™ (aprocitentan)	Systemic hypertension in combination with other antihypertensives	Dual endothelin receptor antagonist	**To be defined:** worldwide development and commercialization rights	■	■	■	■	■	Commercially available in the US
JERAYGO™ (aprocitentan)	Resistant hypertension in combination with other antihypertensives	Dual endothelin receptor antagonist	**To be defined:** worldwide development and commercialization rights	■	■	■	■	□	Approved in the EU and UK; Marketing authorization applications submitted in Canada, and Switzerland
QUVIVIQ™ (daridorexant)	Insomnia	Dual orexin receptor antagonist	**Nxera Pharma:** license to develop and commercialize for Asia-Pacific region (exluding China)	■	■	■	■	□	Launched for the treatment of insomnia in Japan; Phase 3 ongoing in South Korea
Daridorexant	Insomnia	Dual orexin receptor antagonist	**Simcere:** license to develop and commercialize for Greater China region	■	■	■	■	□	NDA submitted in Greater China; approved for the treatment of insomnia in Hong-Kong
Selatogrel	Acute myocardial infarction	$P2Y_{12}$ inhibitor	**Viatris:** worldwide development and commercialization rights	■	■	■	□	□	Phase 3 "SOS-AMI" program ongoing
Cenerimod	Systemic lupus erythematosus	$S1P_1$ receptor modulator	**Viatris:** worldwide development and commercialization rights	■	■	■	□	□	Phase 3 "OPUS" program ongoing
Daridorexant	Posttraumatic stress disorder (PTSD)	Dual orexin receptor antagonist	**US Department of Defense (DOD):** Idorsia is supporting a clinical study sponsored by the US DOD to develop new therapies to treat PTSD	■	■	□	□	□	Phase 2 ongoing
ACT-1002-4391	Immuno-oncology	EP_2 / EP_4 receptor antagonist	**Owkin:** global license to develop and commercialize	■	□	□	□	□	Phase 1 in preparation

P1: Phase 1, P2: Phase 2, P3: Phase 3, R: Registration, C: Commercially available
For more information about our partnerships please visit the **corporate website**

Company milestones

2025

January JERAYGO™ approved by the UK MHRA

2024

September QUVIVIQ launched in Sweden

June JERAYGO approved by the European Union's EMA

March TRYVIO™ approved by the US FDA

March QUVIVIQ launched in France

March Global development and commercialization agreement with Viatris for selatogrel and cenerimod

February QUVIVIQ launched in Austria

2023

November QUVIVIQ launched in Canada

October QUVIVIQ launched in the UK

September QUVIVIQ launched in Spain

June QUVIVIQ launched in Switzerland

2022

December OPUS Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus initiated

November QUVIVIQ launched in Germany and Italy

November The Lancet and American Heart Association late-breaking science session reports significant and sustained effect of aprocitentan on lowering blood pressure for patients with resistant hypertension

May Europe's first dual orexin receptor antagonist – QUVIVIQ – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder

May QUVIVIQ launched in the US

January The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia

2021

December Idorsia to further characterize lucerastat for Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study

September Five Idorsia affiliates in key European markets (France, Germany, Italy, Spain, UK) established

June Initiation of Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction

2020

July Establishment of Idorsia Pharmaceuticals US Inc. to perform commercial operations

2017

June Idorsia opens its doors and is listed on SIX Swiss Stock Exchange

Idorsia is an independent biopharmaceutical company based on science and innovation. The company is specialized in the discovery, development, and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. It is headquartered in Allschwil/Basel, Switzerland and is quoted on the SIX Swiss Exchange (tickersymbol: IDIA). All trademarks are legally protected by their respective owners.

Disclaimer This fact sheet has the sole purpose to provide members of the public with general information about the activities of Idorsia. The forward-looking statements in this fact sheet are based on current expectations and belief of company management, which are subject to numerous risks and uncertainties.

Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil
Switzerland

investor.relations@idorsia.com
Phone +41 58 844 10 10
www.idorsia.com



Company Profile

Latest update:
April 2025